Pulmonary hypertension:
Indications for: REVATIO INJECTION
Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in adults who are temporarily unable to take oral Revatio.
Adult Dosage:
Give by IV bolus inj. 10mg three times daily.
Children Dosage:
Not recommended.
REVATIO INJECTION Contraindications:
Concomitant organic nitrates, riociguat.
REVATIO INJECTION Warnings/Precautions:
Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia (risk of vaso-occlusive crisis). Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP<90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa: not recommended. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy. Nursing mothers.
See Also:
REVATIO INJECTION Classification:
Phosphodiesterase type 5 inhibitor (cGMP-specific).
REVATIO INJECTION Interactions:
See Contraindications. Hypotension with nitrates. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Antagonized by moderate to strong CYP3A4 inducers (eg, bosentan).
Adverse Reactions:
Headache, dyspepsia, flushing, pain in limb, myalgia, back pain, diarrhea; priapism, hypotension, vision or hearing loss.
Drug Elimination:
Fecal (~80%), renal (13%).
Generic Drug Availability:
Tabs (YES); Susp, inj (NO)
How Supplied:
Tabs—90; Susp—112mL (w. bottle adapter, oral syringe); Single-use vial (12.5mL)—1
